From: Clusters of comorbidities in fibrotic hypersensitivity pneumonitis
Clinical characteristics | Entire cohort (n = 211) | Cluster 1 (n = 99) | Cluster 2 (n = 65) | Cluster 3 (n = 47) | ||
---|---|---|---|---|---|---|
Male, n (%) | 113 (53.6%) | 57 (57.6%) | 46 (70.8%) ** | 10 (21.3%) ** | ||
Age at diagnosis, years (SD) | 63.0 (13.3) | 59.3 (14.3) ** | 69.8 (10.2) ** | 61.3 (11.4) | ||
Smoking status, n (%) | ||||||
Never | 106 (50.2%) | 47 (48.0%) | 32 (49.2%) | 27 (57.4%) | ||
Former | 95 (45.2%) | 45 (45.9%) | 32 (49.2%) | 18 (38.3%) | ||
Current | 9 (4.3%) | 6 (6.1%) | 1 (1.5%) | 2 (4.3%) | ||
Pack years (IQR) | 0 (0–20) | 2 (0–20) | 0 (0–30) | 0 (0–10) | ||
FVC, % predicted (SD) | 72.7 (21.2) | 72.9 (18.2) | 74.0 (25.8) | 70.3 (20.5) | ||
TLC, % predicted (SD) | 74.1 (15.9) | 76.7 (14.6) * | 71.3 (17.7) | 72.6 (15.4) | ||
DLCO, % predicted (SD) | 44.1 (13.9) | 46.3 (13.4)* | 42.6 (14.9) | 41.2 (13.2) | ||
6MWD, m (SD) | 373.4 (112.1) | 402.0 (102.4)** | 354.8 (109.0) | 334.8 (122.8)* | ||
Long-term oxygen therapy, n (%) | 39 (18.5%) | 12 (12.1%)* | 18 (27.7%)* | 9 (19.1%) | ||
Lymphocytes in BAL, % of total (IQR) | 24% (10–56%) | 30% (14–61%)* | 23% (6–48%) | 21% (8–57%) | ||
Biopsy (transbronchial cryobiopsi or surgical lung biopsy), n (%) | 83 (39.3%) | 45 (45.5%) | 17 (26.2%)* | 21 (44.7%) | ||
ILD-GAP index, n (%) | ||||||
0–1 | 96 (45.5%) | 57 (57.6%) | * | 15 (23.4%) | ** | 24 (54.5%) |
2–3 | 87 (41.2%) | 34 (34.3%) | 37 (57.8%) | 16 (36.4%) | ||
4–5 | 19 (9.0%) | 6 (6.1%) | 9 (14.1%) | 4 (9.1%) | ||
> 5 | 5 (2.4%) | 2 (2.0%) | 3 (4.7%) | 0 (0.0%) |